Johnson & Johnson (JNJ) Receives Average Rating of “Hold” from Analysts

Shares of Johnson & Johnson (NYSE:JNJ) have earned an average rating of “Hold” from the twenty-two ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $144.41.

Several research firms recently commented on JNJ. Vetr raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective on the stock in a research note on Monday, October 30th. Citigroup boosted their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Jefferies Group boosted their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Finally, Barclays boosted their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 18th.

Shares of Johnson & Johnson (JNJ) traded down $0.48 on Friday, hitting $139.33. 8,941,800 shares of the stock were exchanged, compared to its average volume of 5,873,273. The company has a market cap of $374,310.00, a price-to-earnings ratio of 19.61, a price-to-earnings-growth ratio of 2.85 and a beta of 0.82. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the previous year, the firm posted $1.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. sell-side analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.41%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

Several institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Harding Loevner LP bought a new position in shares of Johnson & Johnson during the second quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. boosted its position in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares during the last quarter. IHT Wealth Management LLC boosted its position in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after acquiring an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson during the second quarter worth $124,000. 65.91% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Receives Average Rating of “Hold” from Analysts” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/01/johnson-johnson-jnj-receives-average-rating-of-hold-from-analysts-2.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply